Focuses on the scrutiny of gene therapy by the U.S. Food and Drug Administration. Reason behind the decision of the FDA to delay all human gene therapy trials at the Institute for Human Genome Therapy, Pennsylvania; Lack of reporting of adverse effects of gene therapy by researchers; Requirements of the National Institute of Health's funding guidelines.